Press-release for stocks for nvsef

t-cell symbols : Nvsef

save search

Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.615 0.89% 9.9M

Health Technology

| -10.59% | O: 0.39% H: 0.82% C: -0.74%
NVS | $93.815 1.35% 410K

Health Technology

| -13.6% | O: 0.22% H: 0.43% C: -0.39%
SRNE | $0.024 57K

Health Technology

| -33.33% | O: -63.33% H: 263.64% C: 127.27%
GILD | News | $66.495 0.51% 1.9M

Health Technology

| -15.83% | O: 0.1% H: 0.43% C: -0.04%
AUTL | $4.73 -1.46% 99K

Health Technology

| -11.96% | O: -0.91% H: 11.52% C: 4.94%
drug report t-cell global therapy market

T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.
Published: 2023-11-06 (Crawled : 15:00) - prnewswire.com
NVS | $93.815 1.35% 410K

Health Technology

| 0.34% | O: 0.54% H: 0.73% C: 0.2%
t-cell research therapy market

Cell Therapy Market to grow by USD 31.04 billion from 2022 to 2027 | Proven effectiveness of CAR T-cell therapy boosts the market - Technavio
Published: 2023-10-04 (Crawled : 18:00) - prnewswire.com
LSTA | $2.85 960

Manufacturing

| 34.3% | O: 3.86% H: 0.93% C: -2.33%
ALPMY | $9.47 520K

Manufacturing

| -30.87% | O: 0.59% H: 0.29% C: 0.22%
NVS | $93.815 1.35% 410K

Health Technology

| -3.25% | O: -1.21% H: 1.3% C: 1.16%
BCLI | $0.484 -5.89% 210K

Health Technology

| 168.42% | O: -0.37% H: 10.94% C: -4.38%
t-cell cell therapy market

CAR T-Cell Therapy Market size to grow at a CAGR of 13.44% from 2022 to 2027; Growing Awareness Regarding CAR T-cell Therapy to boost the market growth- Technavio.
Published: 2023-08-09 (Crawled : 08:00) - prnewswire.com
GLAXF | $20.2 510

Health Technology

| 17.85% | O: 1.92% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 12.8% | O: 1.11% H: 0.53% C: 0.53%
NVS | $93.815 1.35% 410K

Health Technology

| -9.67% | O: -0.07% H: 0.73% C: 0.36%
GSK | $39.685 1.06% 380K

Health Technology

| 13.21% | O: 0.14% H: 0.8% C: 0.43%
GILD | News | $66.495 0.51% 1.9M

Health Technology

| -16.46% | O: 0.61% H: 1.07% C: -0.5%
AUTL | $4.73 -1.46% 99K

Health Technology

| 63.64% | O: -2.02% H: 3.44% C: 2.75%
t-cell growing therapy market

Global Chimeric Antigen Receptor T (CAR-T) Cells Market 2023: Industry Analysis Report Examines the $2.76 Billion Market
Published: 2023-06-29 (Crawled : 18:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| 13.52% | O: 1.03% H: 0.0% C: -4.47%
NVS | $93.815 1.35% 410K

Health Technology

| -6.32% | O: 0.74% H: 0.81% C: 0.81%
BMY | $48.56 0.54% 1.8M

Health Technology

| -24.53% | O: 0.44% H: 0.2% C: -0.51%
AUTL | $4.73 -1.46% 99K

Health Technology

| 113.16% | O: 1.75% H: 3.97% C: 2.59%
report global market

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
Published: 2023-02-16 (Crawled : 15:20) - globenewswire.com
NVS | $93.815 1.35% 410K

Health Technology

| 6.77% | O: -1.48% H: 0.55% C: 0.08%
PDSB | $2.855 -1.55% 240K

Health Technology

| -66.89% | O: -0.11% H: 2.74% C: -1.37%
preclinical biotech publication

CAR-T Cell Therapy Market Size to Reach USD 9.62 Million in 2030| Emergen Research
Published: 2023-01-09 (Crawled : 16:00) - prnewswire.com
ALPMF | $9.17 16K

Health Technology

| -32.44% | O: 3.03% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 24.84% | O: 3.12% H: 0.0% C: -2.55%
ALPMY | $9.47 520K

Manufacturing

| -35.94% | O: 0.58% H: 0.44% C: -0.31%
NVS | $93.815 1.35% 410K

Health Technology

| 0.86% | O: 0.76% H: 0.26% C: -3.27%
LLY | $731.1 -1.99% 1M

Health Technology

| 106.86% | O: 0.29% H: 0.27% C: -3.89%
BMY | $48.56 0.54% 1.8M

Health Technology

| -33.84% | O: 0.16% H: 0.05% C: -2.89%
BNTX | $87.02 0.99% 140K

Health Technology

| -42.59% | O: 1.42% H: 0.64% C: -2.27%
research car-t therapy market

T-cell lymphoma Market 2026, Growing Geriatric Population to Boost Growth - Technavio
Published: 2022-09-26 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 600K

Health Technology

| 26.36% | O: 5.77% H: 0.0% C: -2.27%
AZNCF | $138.24 800

Health Technology

| 24.88% | O: -1.15% H: 0.0% C: -2.43%
NVS | $93.815 1.35% 410K

Health Technology

| 22.46% | O: -2.04% H: 0.82% C: 0.2%
BAX | $39.945 0.74% 430K

Health Technology

| -28.35% | O: -0.45% H: 0.6% C: -0.45%
ABBV | News | $164.91 0.15% 1.2M

Health Technology

| 15.45% | O: -0.69% H: 0.51% C: -0.61%
SNY | News | $46.34 2.09% 620K

Health Technology

| 18.58% | O: -2.29% H: 0.35% C: -0.67%
BIIB | $191.45 0.49% 310K

Health Technology

| -1.33% | O: -0.17% H: 1.2% C: -0.86%
AUTL | $4.73 -1.46% 99K

Health Technology

| 138.24% | O: 2.94% H: 1.43% C: -0.48%
AZN | $68.545 0.27% 1.2M

Health Technology

| 25.07% | O: -1.52% H: 0.48% C: -1.36%
growing t-cell growth market

Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
Published: 2022-08-12 (Crawled : 14:20) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| 34.17% | O: 1.51% H: 0.0% C: 0.0%
NVS | $93.815 1.35% 410K

Health Technology

| 8.76% | O: -0.61% H: 0.9% C: 0.73%
BMY | $48.56 0.54% 1.8M

Health Technology

| -35.13% | O: 0.16% H: 1.53% C: 1.33%
DTIL | $10.465 -2.38% 33K

Health Technology

| 557.67% | O: 0.61% H: 23.78% C: 22.56%
PSTX | News | $2.04 2.0% 120K

Health Technology

| -50.24% | O: -1.7% H: 12.62% C: 8.91%
GILD | News | $66.495 0.51% 1.9M

Health Technology

| 7.13% | O: 0.42% H: 0.45% C: 0.4%
CABA | $13.86 -0.79% 130K

Health Technology

| 1023.45% | O: 2.76% H: 4.7% C: 2.68%
BLCM | $0.0748 381.28% 6.1K

Health Technology

| -94.73% | O: 3.58% H: 1.99% C: -1.41%
ATNX | $0.2031 -7.78% 1.9M

Health Technology

| -62.24% | O: 2.25% H: 0.0% C: 0.0%
AMGN | $265.32 0.98% 550K

Health Technology

| 6.68% | O: 0.07% H: 0.54% C: -0.05%
global report funding therapy market

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Published: 2022-05-27 (Crawled : 23:00) - globenewswire.com
NVS | $93.815 1.35% 410K

Health Technology

| Email alert Add to watchlist
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
kymriah fda novartis car-t therapy

Worldwide T-cell Lymphoma Industry to 2028 - Featuring Genmab, Seagen and GlaxoSmithKline Among Others
Published: 2022-04-28 (Crawled : 21:00) - prnewswire.com
GNMSF | $290.38 220

Health Technology

| -19.57% | O: 2.93% H: 1.47% C: 1.33%
GLAXF | $20.2 510

Health Technology

| -27.34% | O: -0.45% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

Health Technology

| 24.5% | O: -1.05% H: 0.0% C: -0.99%
NVS | $93.815 1.35% 410K

Health Technology

| 4.5% | O: 0.19% H: 0.59% C: -1.36%
GSK | $39.685 1.06% 380K

Health Technology

| -12.33% | O: 0.89% H: 0.0% C: 0.0%
BMY | $48.56 0.54% 1.8M

Health Technology

| -36.9% | O: -3.61% H: 3.02% C: 2.02%
BHC | $8.655 0.64% 750K

Health Technology

| -55.72% | O: -1.67% H: 0.0% C: 0.0%
GMAB | $28.67 1.2% 41K

Health Technology

| -18.65% | O: 1.4% H: 0.82% C: -1.07%
t-cell

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $93.815 1.35% 410K

Health Technology

| 8.28% | O: 1.14% H: 0.0% C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell

Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| 4.78% | O: 1.26% H: 0.0% C: 0.0%
NVS | $93.815 1.35% 410K

Health Technology

| 2.99% | O: 0.02% H: 0.0% C: 0.0%
JNJ | News | $146.39 0.45% 1.8M

Health Technology

| -14.48% | O: -0.53% H: 0.0% C: 0.0%
SRNE | $0.024 57K

Health Technology

| -99.56% | O: -5.96% H: 0.0% C: 0.0%
GILD | News | $66.495 0.51% 1.9M

Health Technology

| -7.26% | O: -0.32% H: 0.0% C: 0.0%
BLUE | $0.9601 0.75% 1.9M

Health Technology

| -89.24% | O: -0.57% H: 0.0% C: 0.0%
cel therapy t-cell

Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research Report 2021: Analysis of Yescarta, Tecartus, Kymriah, Breyanzi, & Abecma
Published: 2021-12-24 (Crawled : 14:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| Email alert Add to watchlist
ABBV | News | $164.91 0.15% 1.2M

Health Technology

| Email alert Add to watchlist
NVS | $93.815 1.35% 410K

Health Technology

| Email alert Add to watchlist
CYAD | $0.47 -12.49% 49K

Health Technology

| Email alert Add to watchlist
yescarta research kymriah cel therapy t-cell

NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
NVS | $93.815 1.35% 410K

Health Technology

| 13.54% | O: 0.46% H: 0.62% C: 0.08%
phase 1 phase 1b t-cell phase 2b

Global CAR-T Cell Therapy Markets to 2026: Rising Clinical Trials and Development of New and Effective Therapy Options
Published: 2021-09-28 (Crawled : 16:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K

Health Technology

| 14.67% | O: -0.12% H: 1.77% C: -0.99%
NVS | $93.815 1.35% 410K

Health Technology

| 12.7% | O: 0.16% H: 0.04% C: -0.51%
JNJ | News | $146.39 0.45% 1.8M

Health Technology

| -11.17% | O: -0.04% H: 0.5% C: -0.18%
ABBV | News | $164.91 0.15% 1.2M

Health Technology

| 53.32% | O: -0.09% H: 0.93% C: -0.26%
SGMO | $0.5151 6.18% 340K

Health Technology

| -94.69% | O: -1.12% H: 0.52% C: -2.17%
AUTL | $4.73 -1.46% 99K

Health Technology

| -31.74% | O: -2.67% H: 1.27% C: -5.48%
AMGN | $265.32 0.98% 550K

Health Technology

| 24.32% | O: -0.38% H: 1.16% C: -0.01%
clinical trials therapy car-t trials trial t-cell

t-cell symbols : Nvsef

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

t-cell symbols : Nvsef save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

t-cell symbols : Nvsef

save search